Fig. 2
TA mediates sensitivity to lapatinib in intrinsically resistant breast cancer cells. a Dose–response curves of MDA-MB-361 cells carrying shNT or shTA constructs. (n = 4). Western blot showing shRNA knockdown efficiency. b Fold change of cell numbers at the indicated time points in shNT or shTA cells treated with DMSO or 4 μM lapatinib (n = 3). c Numbers of MDA-MB-453 cells cultured with DMSO or 1 μM lapatinib for 3 days and co-treated with either shNT or shTA (n = 3). d Dose-response curves of BT474 and rBT474 cells carrying shNT or shTA constructs (n = 4). Western blot showing shRNA knockdown efficiency. IC50s were calculated using Prism curve fit (variable slope) default program. Error bars denote the SD; n.s., not significant; *P < 0.05; **P < 0.005; ***P < 0.001 by unpaired, two-tail, student t-test
